Crinetics Pharmaceuticals (CRNX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 18, 2026, with record date April 20, 2026, to elect three Class II directors, ratify PwC as auditor, and hold a say-on-pay vote for executive compensation.

• Virtual-only meeting format with multiple voting options, including online, phone, and mail.

• Forward-looking statements highlight commercialization plans for PALSONIFY, clinical development timelines, and risk factors including regulatory, operational, and geopolitical uncertainties.

Voting matters and shareholder proposals

• Three proposals: election of three Class II directors, ratification of PwC as independent auditor for 2026, and advisory approval of executive compensation.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2027 meeting must be submitted by December 30, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• Board divided into three classes; majority are independent directors.

• Board skills matrix covers leadership, finance, clinical, regulatory, and commercialization expertise.

• Board leadership is separated between CEO and independent chair.

• Five standing committees: audit, compensation, nominating and corporate governance, research and development, and global therapeutics strategy and access.

• Board diversity includes three female directors and two from underrepresented communities.

• Insider trading policy prohibits hedging, pledging, and margin transactions.